JP2025020119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025020119A5 JP2025020119A5 JP2024174007A JP2024174007A JP2025020119A5 JP 2025020119 A5 JP2025020119 A5 JP 2025020119A5 JP 2024174007 A JP2024174007 A JP 2024174007A JP 2024174007 A JP2024174007 A JP 2024174007A JP 2025020119 A5 JP2025020119 A5 JP 2025020119A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- administered
- composition according
- hodgkin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344880P | 2016-06-02 | 2016-06-02 | |
| US62/344,880 | 2016-06-02 | ||
| JP2018563008A JP7175198B2 (ja) | 2016-06-02 | 2017-06-01 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| PCT/US2017/035492 WO2017210453A1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
| JP2022178836A JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178836A Division JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025020119A JP2025020119A (ja) | 2025-02-12 |
| JP2025020119A5 true JP2025020119A5 (enExample) | 2025-06-23 |
Family
ID=59067911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563008A Active JP7175198B2 (ja) | 2016-06-02 | 2017-06-01 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2022178836A Active JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2024174007A Pending JP2025020119A (ja) | 2016-06-02 | 2024-10-03 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563008A Active JP7175198B2 (ja) | 2016-06-02 | 2017-06-01 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2022178836A Active JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11083790B2 (enExample) |
| EP (2) | EP4248990A3 (enExample) |
| JP (3) | JP7175198B2 (enExample) |
| KR (2) | KR20230038318A (enExample) |
| CN (1) | CN109475633A (enExample) |
| DK (1) | DK3463457T3 (enExample) |
| ES (1) | ES2954139T3 (enExample) |
| FI (1) | FI3463457T3 (enExample) |
| HR (1) | HRP20230864T1 (enExample) |
| HU (1) | HUE062398T2 (enExample) |
| LT (1) | LT3463457T (enExample) |
| PL (1) | PL3463457T3 (enExample) |
| PT (1) | PT3463457T (enExample) |
| RS (1) | RS64388B1 (enExample) |
| SI (1) | SI3463457T1 (enExample) |
| SM (1) | SMT202300290T1 (enExample) |
| WO (1) | WO2017210453A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| FI3334763T3 (fi) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Uusia pd-l1-vasta-aineita |
| BR112018074619A2 (pt) | 2016-06-02 | 2019-03-06 | Bristol Myers Squibb Co | uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer |
| FI3463457T3 (fi) | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa |
| US11572405B2 (en) * | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| US20220041733A1 (en) * | 2019-03-28 | 2022-02-10 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20060032289A1 (en) | 2004-08-11 | 2006-02-16 | Pinnaduwage Lal A | Non-optical explosive sensor based on two-track piezoresistive microcantilever |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US9107887B2 (en) | 2011-03-10 | 2015-08-18 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| FI3463457T3 (fi) | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa |
-
2017
- 2017-06-01 FI FIEP17730627.1T patent/FI3463457T3/fi active
- 2017-06-01 JP JP2018563008A patent/JP7175198B2/ja active Active
- 2017-06-01 US US16/306,285 patent/US11083790B2/en active Active
- 2017-06-01 LT LTEPPCT/US2017/035492T patent/LT3463457T/lt unknown
- 2017-06-01 ES ES17730627T patent/ES2954139T3/es active Active
- 2017-06-01 KR KR1020237008131A patent/KR20230038318A/ko not_active Ceased
- 2017-06-01 EP EP23174335.2A patent/EP4248990A3/en active Pending
- 2017-06-01 SM SM20230290T patent/SMT202300290T1/it unknown
- 2017-06-01 HU HUE17730627A patent/HUE062398T2/hu unknown
- 2017-06-01 HR HRP20230864TT patent/HRP20230864T1/hr unknown
- 2017-06-01 KR KR1020187037835A patent/KR20190015377A/ko not_active Ceased
- 2017-06-01 PT PT177306271T patent/PT3463457T/pt unknown
- 2017-06-01 RS RS20230598A patent/RS64388B1/sr unknown
- 2017-06-01 WO PCT/US2017/035492 patent/WO2017210453A1/en not_active Ceased
- 2017-06-01 CN CN201780047962.4A patent/CN109475633A/zh active Pending
- 2017-06-01 SI SI201731382T patent/SI3463457T1/sl unknown
- 2017-06-01 EP EP17730627.1A patent/EP3463457B1/en active Active
- 2017-06-01 DK DK17730627.1T patent/DK3463457T3/da active
- 2017-06-01 PL PL17730627.1T patent/PL3463457T3/pl unknown
-
2021
- 2021-08-09 US US17/397,221 patent/US20220025049A1/en not_active Abandoned
-
2022
- 2022-11-08 JP JP2022178836A patent/JP7568698B2/ja active Active
-
2024
- 2024-10-02 US US18/905,043 patent/US20250134996A1/en active Pending
- 2024-10-03 JP JP2024174007A patent/JP2025020119A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020119A5 (enExample) | ||
| Korbelik et al. | Photodynamic therapy-mediated immune response against subcutaneous mouse tumors | |
| JP2019532080A5 (enExample) | ||
| JP2019517504A5 (enExample) | ||
| JP2022000060A5 (enExample) | ||
| WO2017042944A1 (ja) | フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法 | |
| JP2014512391A5 (enExample) | ||
| US20200171061A1 (en) | Methods for Cancer Therapy | |
| CN109414443A (zh) | 用于降低类固醇剂量并治疗炎性和自身免疫性疾病的大麻二酚 | |
| Chen et al. | Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms | |
| Cheung | AIDS-Related Cancer in the Era of Highly Active Antiretroviral Therapy (HAART): A Model of the Interplay of the Immune System, Virus, and Cancer.—“On the Offensive—The Trojan Horse is Being Destroyed”—Part A: Kaposi's Sarcoma | |
| Taha et al. | Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection | |
| CN113440533B (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JP2023011549A5 (enExample) | ||
| JPS63183528A (ja) | 悪性腫瘍治療剤 | |
| EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
| JPWO2022240688A5 (enExample) | ||
| WO2021150756A1 (en) | Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer | |
| US20230060792A1 (en) | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy | |
| JP2018522881A5 (enExample) | ||
| JP2005502690A5 (enExample) | ||
| Traynor et al. | Hematopoietic stem cell transplantation for systemic lupus erythematosus | |
| Chassagne et al. | Progress report of a Phase II and a Phase III trial with etanidazole (SR-2508): A multicentre European study | |
| US20220339175A1 (en) | Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate Cancer | |
| Chaudhry | Novel intercepts for Multiple Myeloma |